



NUTRITION UNIT

## SCIENTIFIC PANEL ON NUTRITION, NOVEL FOODS AND FOOD ALLERGENS

### MINUTES OF THE 100<sup>TH</sup> PLENARY MEETING

**Held on 23-25 March 2020 via web conference<sup>1</sup>  
(Agreed on 1<sup>st</sup> April 2020)**

#### Participants

■ Panel Members:

Jacqueline Castenmiller, Stefaan de Henauw, Karen Ildico Hirsch-Ernst, John Kearney, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J. McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Dominique Turck (Chair) and Marco Vinceti.

■ Hearing Experts:

Not Applicable

■ European Commission:

Panagiotis Daskaleros, Ivona Babic<sup>2</sup>, Fruzsina Nyemecz<sup>3</sup>, Rafael Perez-Berbejal<sup>4</sup>

■ EFSA:

NUTRI Unit: Valeriu Curtui, Reinhard Ackerl, Paolo Colombo, Agnès de Sesmaisons-Lecarré, Céline Dumas, Wolfgang Gelbmann, Andrea Germini, Leng Heng, Leonard Matijevic, Ariane Titz, Emanuela Turla, Silvia Valtueña Martínez.

■ Others:

Not Applicable

<sup>1</sup> This meeting, originally scheduled as a physical meeting, was converted into a teleconference to avoid traveling to EFSA in line with the measures established to reduce the risk of coronavirus infection

<sup>2</sup> Attended only 23<sup>rd</sup> and 25<sup>th</sup>

<sup>3</sup> Attended only 25<sup>th</sup>

<sup>4</sup> Attended only 23<sup>rd</sup> and 25<sup>th</sup>



## 1. Welcome and apologies for absence

The Chair welcomed the participants. No apologies were received.

## 2. Adoption of agenda

The agenda was adopted with changes in the order of items discussed.

## 3. Declarations of Interest of Scientific Panel members

In accordance with EFSA's Policy on Independence<sup>5</sup> and the Decision of the Executive Director on Competing Interest Management<sup>6</sup>, EFSA screened the Annual Declarations of Interest filled out by the Panel members invited to the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process, and no interests were declared orally by the members at the beginning of this meeting.

## 4. Agreement of the minutes of the 99<sup>th</sup> Plenary meeting held on 25 February 2020 via web conference

The **minutes of the 99th Plenary meeting** held on 25 February 2020 were agreed by written procedure on 02 March 2020.

## 5. Scientific outputs submitted for discussion and/or possible adoption

### 5.1. Draft opinion on 6'-sialyllactose (6'-SL) as a novel food (NF 2019/0881) - Applicant: Glycom A/S (EFSA-Q-2019-00169)

The draft opinion was presented. The Panel reviewed and discussed the sections regarding composition, production process, specifications, proposed uses and use levels, anticipated daily intake, nutritional information, toxicology and allergenicity of the Novel Food. The opinion was adopted by the Panel on 23 March subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6097>

### 5.2. Draft opinion on 3'-sialyllactose (3'-SL) sodium salt as a novel food (NF 2019/0957) - Applicant: Glycom A/S (EFSA-Q-2019-00204)

The draft opinion was presented. The Panel reviewed and discussed the sections regarding composition, production process, specifications, proposed uses and use levels, anticipated daily intake, nutritional information, toxicology and allergenicity of the Novel Food. The opinion was adopted by the Panel on 25 March subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6098>

<sup>5</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/policy\\_independence.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf)

<sup>6</sup> [http://www.efsa.europa.eu/sites/default/files/corporate\\_publications/files/competing\\_interest\\_management\\_17.pdf](http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf)



**5.3. Draft opinion on an extract derived from *Panax notoginseng* and *Astragalus membranaceus* (AstraGin®) as a novel food (NF 2018/0284) - Applicant: NuLiv Science (EFSA-Q-2018-00557)**

The draft opinion was presented. The Panel reviewed and discussed the sections regarding composition, production process, specifications, proposed uses and use levels, anticipated daily intake, nutritional information, toxicology and allergenicity of the Novel Food. The opinion was adopted by the Panel on 24 March subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6099>

**5.4. Draft opinion on dried whole cell *Euglena* as a novel food (NF 2018/0669) - Applicant: Kemin Foods L.C. (EFSA-Q-2019-00043)**

The draft opinion was presented. The Panel reviewed and discussed the sections regarding composition, production process, specifications, proposed uses and use levels, anticipated daily intake, nutritional information, toxicology and allergenicity of the Novel Food. The opinion was adopted by the Panel on 25 March subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal via the following link: <http://www.efsa.europa.eu/en/efsajournal/pub/6100>

## 6. New mandates

Postponed.

## 7. Feedback from the Scientific Committee/Scientific Panels, EFSA, the European Commission

Postponed.

## 8. Other scientific topics for information and/or discussion

**8.1. Draft explanatory note to the scientific and technical guidance for the preparation and presentation of an application for authorisation of an infant and/or follow-on formula manufactured from protein hydrolysates (EFSA-Q-2019-00805)**

The draft explanatory note was presented to the Panel. It intends to provide further clarification on certain requirements outlined in the scientific and technical guidance for the preparation and presentation of an application for authorisation of an infant and/or follow-on formula manufactured from protein hydrolysates. The draft explanatory note addresses in particular: (1) the scope of the nutritional safety and suitability assessment; (2) the control formulae that are used in studies to demonstrate the nutritional safety and suitability of a protein hydrolysate; (3) information to be provided in relation to the enzyme(s) that is/are used in the production of the protein hydrolysates; (4) information needed for characterisation of a protein hydrolysate and its conditions of use; and (5) clarifications on data requirements in relation to the characterisation of the protein hydrolysate/formula.



The Panel members were asked to provide written input after the meeting. The draft explanatory note will be re-discussed at the NDA Plenary in April 2020.

## **8.2. Draft opinion on phytosterol esters (extension of use, cooking oils) as a novel food - Applicant: Upfield (EFSA-Q-2014-00865)**

The Panel was given an overview on the background and data submitted in the application for an extension of use (for cooking purposes) concerning the authorised Novel Food “plant sterols” (PS), including the additional information sent by the applicant in response to a request by EFSA. The stability data, the intake assessment, the nutritional information, the toxicological and human data were presented. The draft opinion will be further considered and elaborated by the WG on Novel Foods, prior to its submission to the NDA Panel<sup>7</sup> for discussion/possible adoption.

## **9. Any Other Business**

The next plenary meeting of the NDA Panel is scheduled on 20-21 April 2020 via web conference.

---

<sup>7</sup> NDA Panel Plenary of 5-7 May 2020